About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Novel Breakthrough may Block the Progression of Multiple Sclerosis

by Bidita Debnath on April 14, 2016 at 3:08 AM
Font : A-A+

 Novel Breakthrough may Block the Progression of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic incurable condition marked by attacks that bring gradual deterioration in the patient's health. A new plant-derived drug can block the progression of MS, demonstrates an international research team.

University of Queensland researcher Dr Christian Gruber said the breakthrough could be a step forward in preventing and treating MS and other autoimmune diseases. "This is a really exciting discovery because it may offer a whole new quality of life for people with this debilitating disease," he said.

Advertisement


The new drug is expected to be taken by mouth, in contrast to some current MS treatments where patients need to have frequent injections. About 23,000 people are affected in Australia and 2.5 million worldwide.

Dr Gruber said the new drug -- named T20K -- was extracted from a traditional medicinal plant, the Oldenlandia affinis. The drug treatment had been successful in an animal model, and patent applications filed in several countries. "Phase one clinical trials could begin as early as 2018," Dr Gruber said.
Advertisement

"Licences have been assigned to Cyxone, a company established last year to develop this new class of drugs for the treatment of autoimmune diseases. "Cyxone's immediate focus is on bringing T20K through the pre-clinical program required for delivering a safe, orally active drug."

Dr Gruber said the new treatment arose from a synthesised plant peptide, a class of drugs known as cyclotides. "Cyclotides are present in a range of common plants, and they show significant potential for the treatment of auto immune diseases," he said.

"The T20K peptides exhibit extraordinary stability and chemical features that are ideally what you want in an oral drug candidate." The international research team demonstrated in an animal model that T20K stopped progression in the normal clinical symptoms of MS.

Dr Gruber, from UQ's School of Biomedical Sciences, is also an international research fellow at the Center for Physiology and Pharmacology at the Medical University of Vienna. He and his colleagues published their breakthrough research in PNAS.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Liver Transplantation
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chemotherapy Chemotherapy Drugs Infectious Mononucleosis Multiple Sclerosis Treatment and Modify Optic Neuritis Autoimmune Disorders Health Risks of Eating Pork 

Most Popular on Medindia

Sinopril (2mg) (Lacidipine) Pregnancy Confirmation Calculator Loram (2 mg) (Lorazepam) Find a Hospital Drug Interaction Checker Diaphragmatic Hernia Noscaphene (Noscapine) Color Blindness Calculator Daily Calorie Requirements Find a Doctor
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use